ASCO 2021

Complete Coverage

New Therapies on the Horizon for Elderly or Frail Patients With Head and Neck Cancer

A nanoparticle-radiotherapy regimen and a chemoimmunotherapy regimen both appear safe and effective for this population.

Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer

Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.

Liquid Biopsy-Guided Therapy Improves Survival in Lung Cancer

Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.

On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management

Dr Alan Lyss reviews results from the high-risk cohort of the WSG-ADAPT HR+/HER2- trial.

Less Than Half of NSCLC Patients Received Comprehensive Biomarker Testing in a Real-World Study

Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.

Antibody-Drug Conjugate Proves Active in Advanced, Resistant EGFR-Mutated Lung Cancer

Responses were observed across EGFR TKI resistance mechanisms.

Durvalumab Improves Survival When Added to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Durvalumab improved invasive disease-free survival, distant disease-free survival, and overall survival.

Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women

Data showed increases in endometrial cancer and obesity in women younger than 40.

Combination Anlotinib and Sintilimab Exhibits Antitumor Activity in Advanced Endometrial Cancer

Nearly three-quarters of patients responded to treatment.

Genomic Signature May Identify Breast Cancer Patients Who Can Safely Forgo Adjuvant Radiotherapy

The signature was prognostic for locoregional recurrence.

Chemotherapy Doesn’t Increase the Risk of COVID-19 or Related Death in Patients with Breast Cancer, Study Suggests

Rates of SARS-CoV-2 infection and COVID-19-related death were similar among patients receiving cytotoxic and non-cytotoxic therapy.

Endocrine Therapy Proves Noninferior to Chemotherapy in HR+, HER2+ Metastatic Breast Cancer

Endocrine therapy was associated with fewer adverse events.

Mobile Wearable Devices Show Some Sleep Disturbances During Multiple Myeloma Treatment

Younger patients had a significant decrease in sleep time on days they received dexamethasone.

Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases

Black patients were more likely than White patients to have distant metastases.

Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.

Bone-Protecting Agents Reduce Fractures Associated With Treatment in Metastatic Castration-Resistant Prostate Cancer

The cumulative incidence of bone fractures was below 5% in BPA recipients.

Final Results Support Pembrolizumab as Standard of Care in MSI-H/dMMR Metastatic Colorectal Cancer

Pembrolizumab improved progression-free survival but not overall survival.

PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer

The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.

LEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab

In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.

Ivosidenib Plus Venetoclax, With or Without Azacitidine, Appears Effective in IDH1-Mutated Myeloid Malignancies

The 1-year overall survival rate was 71%.